27 related articles for article (PubMed ID: 31296923)
1. Elevated postoperative carcinoembryonic antigen guides adjuvant chemotherapy for stage II colon cancer: a multicentre cohort retrospective study.
Pu H; Yang W; Liu M; Pang X; Chen Y; Xiong Q
Sci Rep; 2024 Mar; 14(1):6889. PubMed ID: 38519578
[TBL] [Abstract][Full Text] [Related]
2. Assessment of Duration and Effects of 3 vs 6 Months of Adjuvant Chemotherapy in High-Risk Stage II Colorectal Cancer: A Subgroup Analysis of the TOSCA Randomized Clinical Trial.
Petrelli F; Labianca R; Zaniboni A; Lonardi S; Galli F; Rulli E; Rosati G; Corallo S; Ronzoni M; Cardellino GG; Mattioli R; Mambrini A; Ciuffreda L; Banzi M; Pusceddu V; Maiello E; Zampino M; Zagonel V; Marchetti P; Corsi D; Rimassa L; Cinieri S; Sobrero A
JAMA Oncol; 2020 Apr; 6(4):547-551. PubMed ID: 32053133
[TBL] [Abstract][Full Text] [Related]
3. Clinical utility of the carcinoembryonic antigen level in patients with stage III colon cancer after surgery and adjuvant chemotherapy.
Udagawa S; Osumi H; Kozuki R; Ooki A; Wakatsuki T; Kurihara N; Mukai T; Yamaguchi T; Akiyoshi T; Fukunaga Y; Yamaguchi K; Shinozaki E
Surg Today; 2023 Dec; ():. PubMed ID: 38103076
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of Serum Fructosamine as Diagnostic Marker of Postoperative Recurrence in the Patients with Breast Cancer.
Zhao Y; Xie X; Xie J; Zhang L; Li B; Liu J; Jiang H
Biomed Res Int; 2023; 2023():6435776. PubMed ID: 37475819
[TBL] [Abstract][Full Text] [Related]
5. Predicting disease-free survival in colorectal cancer by circulating tumor DNA methylation markers.
Yang X; Wen X; Guo Q; Zhang Y; Liang Z; Wu Q; Li Z; Ruan W; Ye Z; Wang H; Chen Z; Fan JB; Lan P; Liu H; Wu X
Clin Epigenetics; 2022 Dec; 14(1):160. PubMed ID: 36457093
[TBL] [Abstract][Full Text] [Related]
6. Clinical Usefulness of Postoperative Serum Carcinoembryonic Antigen in Patients with Colorectal Cancer with Liver Metastases.
Yoshino K; Osumi H; Ito H; Kamiimabeppu D; Ooki A; Wakatsuki T; Shimozaki K; Nakayama I; Ogura M; Takahari D; Chin K; Oba A; Ono Y; Sato T; Inoue Y; Takahashi Y; Yamaguchi K; Shinozaki E
Ann Surg Oncol; 2022 Dec; 29(13):8385-8393. PubMed ID: 35974233
[TBL] [Abstract][Full Text] [Related]
7. High postoperative carcinoembryonic antigen as an indicator of high-risk stage II colon cancer.
Morimoto Y; Takahashi H; Arita A; Itakura H; Fujii M; Sekido Y; Hata T; Fujino S; Ogino T; Miyoshi N; Uemura M; Matsuda C; Yamamoto H; Mizushima T; Doki Y; Eguchi H
Oncol Lett; 2022 May; 23(5):167. PubMed ID: 35414828
[TBL] [Abstract][Full Text] [Related]
8. Lead Time and Prognostic Role of Serum CEA, CA19-9, IL-6, CRP, and YKL-40 after Adjuvant Chemotherapy in Colorectal Cancer.
Lehtomäki K; Mustonen H; Kellokumpu-Lehtinen PL; Joensuu H; Hermunen K; Soveri LM; Boisen MK; Dehlendorff C; Johansen JS; Haglund C; Osterlund P
Cancers (Basel); 2021 Aug; 13(15):. PubMed ID: 34359796
[TBL] [Abstract][Full Text] [Related]
9. Low miR-1273a expression predicts poor prognosis of colon cancer and facilitates tumor cell proliferation, migration, and invasion.
Sun L; Zhou X; Jiang Q; Zhuang Y; Li D
Braz J Med Biol Res; 2021; 54(2):e10394. PubMed ID: 33439933
[TBL] [Abstract][Full Text] [Related]
10. Stage migration resulting from inadequate number of examined lymph nodes impacts prognosis in stage II colon cancer after radical surgery.
Xie D; Song X; Tong L
Int J Colorectal Dis; 2021 May; 36(5):959-969. PubMed ID: 33174134
[TBL] [Abstract][Full Text] [Related]
11. Prognostic Factor and Survival Benefit of Adjuvant Chemotherapy in Stage IIA Colon Cancer.
Lee MW; Kim JS; Kim JY; Lee KH
Ann Coloproctol; 2021 Feb; 37(1):35-43. PubMed ID: 32972104
[TBL] [Abstract][Full Text] [Related]
12. Association of Bevacizumab Plus Oxaliplatin-Based Chemotherapy With Disease-Free Survival and Overall Survival in Patients With Stage II Colon Cancer: A Secondary Analysis of the AVANT Trial.
Chibaudel B; Henriques J; Rakez M; Brenner B; Kim TW; Martinez-Villacampa M; Gallego-Plazas J; Cervantes A; Shim K; Jonker D; Guerin-Meyer V; Mineur L; Banzi C; Dewdney A; Dejthevaporn T; Bloemendal HJ; Roth A; Moehler M; Aranda E; Van Cutsem E; Tabernero J; Schmoll HJ; Hoff PM; André T; de Gramont A
JAMA Netw Open; 2020 Oct; 3(10):e2020425. PubMed ID: 33074326
[TBL] [Abstract][Full Text] [Related]
13. Baseline carcinoembryonic antigen as a predictive factor of ramucirumab efficacy in RAISE, a second-line metastatic colorectal carcinoma phase III trial.
Yoshino T; Obermannová R; Bodoky G; Garcia-Carbonero R; Ciuleanu T; Portnoy DC; Kim TW; Hsu Y; Ferry D; Nasroulah F; Tabernero J
Eur J Cancer; 2017 Jun; 78():61-69. PubMed ID: 28412590
[TBL] [Abstract][Full Text] [Related]
14. Adjuvant Fluorouracil, Leucovorin, and Oxaliplatin in Stage II to III Colon Cancer: Updated 10-Year Survival and Outcomes According to BRAF Mutation and Mismatch Repair Status of the MOSAIC Study.
André T; de Gramont A; Vernerey D; Chibaudel B; Bonnetain F; Tijeras-Raballand A; Scriva A; Hickish T; Tabernero J; Van Laethem JL; Banzi M; Maartense E; Shmueli E; Carlsson GU; Scheithauer W; Papamichael D; Möehler M; Landolfi S; Demetter P; Colote S; Tournigand C; Louvet C; Duval A; Fléjou JF; de Gramont A
J Clin Oncol; 2015 Dec; 33(35):4176-87. PubMed ID: 26527776
[TBL] [Abstract][Full Text] [Related]
15. Risk of recurrence in patients with colon cancer stage II and III: a systematic review and meta-analysis of recent literature.
Böckelman C; Engelmann BE; Kaprio T; Hansen TF; Glimelius B
Acta Oncol; 2015 Jan; 54(1):5-16. PubMed ID: 25430983
[TBL] [Abstract][Full Text] [Related]
16. Association of post-operative CEA with survival and oxaliplatin benefit in patients with stage II colon cancer: a post hoc analysis of the MOSAIC trial.
Auclin E; André T; Taieb J; Banzi M; Van Laethem JL; Tabernero J; Hickish T; de Gramont A; Vernerey D
Br J Cancer; 2019 Aug; 121(4):312-317. PubMed ID: 31296923
[TBL] [Abstract][Full Text] [Related]
17. Preoperative Serum Carcinoembryonic Antigen Level as a Prognostic Factor for Recurrence and Survival After Curative Resection Followed by Adjuvant Chemotherapy in Stage III Colon Cancer.
Kim CG; Ahn JB; Jung M; Beom SH; Heo SJ; Kim JH; Kim YJ; Kim NK; Min BS; Koom WS; Kim H; Roh YH; Ma BG; Shin SJ
Ann Surg Oncol; 2017 Jan; 24(1):227-235. PubMed ID: 27699609
[TBL] [Abstract][Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
